These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 32152876)
41. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109 [TBL] [Abstract][Full Text] [Related]
42. Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients. Murai K; Yamaguchi K; Ito S; Miyagishima T; Shindo M; Wakasa K; Inomata M; Nagashima T; Kondo T; Fujimoto N; Yamamoto S; Yonezumi M; Oyake T; Kowata S; Tsukushi Y; Mine T; Meguro K; Ikeda K; Watanabe R; Saito S; Sato S; Tajima K; Chou T; Kubo K; Oba K; Sakamoto J; Ishida Y; Eur J Haematol; 2018 Jan; 100(1):27-35. PubMed ID: 28895203 [TBL] [Abstract][Full Text] [Related]
48. Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic. Klamova H; Faber E; Zackova D; Markova M; Voglova J; Cmunt E; Novakova L; Machova-Polakova K; Moravcova J; Dvorakova D; Michalova K; Brezinova J; Oltova A; Jarosova M; Cetkovsky P; Indrak K; Mayer J Neoplasma; 2010; 57(4):355-9. PubMed ID: 20429627 [TBL] [Abstract][Full Text] [Related]
49. Diagnosis and Monitoring of Chronic Myeloid Leukemia: Chiang Mai University Experience. Tantiworawit A; Kongjarern S; Rattarittamrong E; Lekawanvijit S; Bumroongkit K; Boonma N; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Norasetthada L Asian Pac J Cancer Prev; 2016; 17(4):2159-64. PubMed ID: 27221912 [TBL] [Abstract][Full Text] [Related]
50. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience). Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630 [TBL] [Abstract][Full Text] [Related]
51. Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety. Huang X; Jiang Q; Hu J; Li J; Jin J; Meng F; Shen Z; Liu T; Wu D; Wang J; Wang J Front Med; 2019 Jun; 13(3):344-353. PubMed ID: 30159669 [TBL] [Abstract][Full Text] [Related]
52. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system. Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347 [TBL] [Abstract][Full Text] [Related]
53. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. Gore L; Kearns PR; de Martino ML; Lee ; De Souza CA; Bertrand Y; Hijiya N; Stork LC; Chung NG; Cardos RC; Saikia T; Fagioli F; Seo JJ; Landman-Parker J; Lancaster D; Place AE; Rabin KR; Sacchi M; Swanink R; Zwaan CM J Clin Oncol; 2018 May; 36(13):1330-1338. PubMed ID: 29498925 [TBL] [Abstract][Full Text] [Related]
54. Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors. Erbilgin Y; Eskazan AE; Hatirnaz Ng O; Salihoglu A; Elverdi T; Firtina S; Tasar O; Mercan S; Sisko S; Khodzhaev K; Ongoren S; Ar MC; Baslar Z; Soysal T; Sayitoglu M; Ozbek U Leuk Lymphoma; 2019 Jan; 60(1):200-207. PubMed ID: 29965782 [TBL] [Abstract][Full Text] [Related]
55. Evaluation of Long-Term Chronic Myeloid Leukemia Treatment Practices with Tyrosine Kinase Inhibitors in a National Cohort of Veterans. Kreys ED; Frei CR; Villarreal SM; Bollinger MJ; Jones X; Koeller JM Pharmacotherapy; 2017 Mar; 37(3):278-286. PubMed ID: 28052354 [TBL] [Abstract][Full Text] [Related]
56. Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data. Gambacorti-Passerini C; Chen C; Davis C; Sen GP; Guyan C; Hehlmann R; Michallet M; Paquette R; Goldberg SL Eur J Haematol; 2021 Jan; 106(1):82-89. PubMed ID: 32989776 [TBL] [Abstract][Full Text] [Related]
57. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014. Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856 [TBL] [Abstract][Full Text] [Related]
58. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. Brümmendorf TH; Cortes JE; Khoury HJ; Kantarjian HM; Kim DW; Schafhausen P; Conlan MG; Shapiro M; Turnbull K; Leip E; Gambacorti-Passerini C; Lipton JH Br J Haematol; 2016 Jan; 172(1):97-110. PubMed ID: 26537529 [TBL] [Abstract][Full Text] [Related]
59. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Fava C; Rege-Cambrin G; Dogliotti I; Cerrano M; Berchialla P; Dragani M; Rosti G; Castagnetti F; Gugliotta G; Martino B; Gambacorti-Passerini C; Abruzzese E; Elena C; Pregno P; Gozzini A; Capodanno I; Bergamaschi M; Crugnola M; Bocchia M; Galimberti S; Rapezzi D; Iurlo A; Cattaneo D; Latagliata R; Breccia M; Cedrone M; Santoro M; Annunziata M; Levato L; Stagno F; Cavazzini F; Sgherza N; Giai V; Luciano L; Russo S; Musto P; Caocci G; Sorà F; Iuliano F; Lunghi F; Specchia G; Pane F; Ferrero D; Baccarani M; Saglio G Haematologica; 2019 Aug; 104(8):1589-1596. PubMed ID: 30819917 [TBL] [Abstract][Full Text] [Related]
60. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]